Description
Our genome is personal, so shouldn't our medicine be as well? As the pace of development in personalized or precision medicine accelerates, many new issues and challenges arise out of the ethical and practical implications around privacy, access, and ownership of personal genomic data. What is the true value of personalized medicine and who pays for it? What technology or information can be protected with patents or other rights? Whether you are in-house counsel or in private practice, this innovative program will tackle these questions and provide insightful answers.

PROGRAM CHAIRS

Geoff Mowatt, DLA Piper (Canada) LLP
Inta Gaikis, Novo Nordisk Canada

TABLE OF CONTENTS

Personalized Medicine - What is it and why are we talking about it?
Roger Tam, Vice-President, Legal, Roche Canada

Bioethics: The Challenges and Opportunities
Ian Stedman, Osgoode Hall Law School, York University

Links to Background Information
Teresa Reguly, Torys LLP
Adrian Thorogood, Regulatory and Ethics Work Stream Manager, Global Alliance for Genomics and Health

Evolving Technology and Protecting Innovation
Graham McNeil, Head of Legal, Celgene Canada
Sara Zborovski, Norton Rose Fulbright LLP

Reimbursement and the Payer Perspective
Wayne Critchley, Global Public Affairs